QUOTE AND NEWS
FierceBiotech  Jul 28  Comment 
Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its...
FierceBiotech  Apr 18  Comment 
A Cambridge, MA-based joint venture marrying the protein and antibody development technology of Crucell with the manufacturing knowhow of Royal DSM for developing biosimilars has collapsed. A spokesperson for Crucell tells FierceBiotech that the...
StreetInsider.com  Feb 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Johnson+%26+Johnson+%28JNJ%29+Proposal+to+Acquire+Crucell+%28CRXL%29+Achieves+Minimum+Acceptance/6307814.html for the full story.
FiercePharma  Feb 11  Comment 
Crucell can exit the penalty box. After a review of manufacturing problems involving its vaccine Quinvaxem, the Dutch company now has the World Health Organization's blessing to resume selling the shot. "WHO is confident that Crucell is operating...
Reuters  Feb 10  Comment 
* WHO says will accept sales of Crucell's childhood vaccines
Reuters  Feb 9  Comment 
Crucell NV shareholder Van Herk said on Wednesday it would tender its shares to U.S. healthcare company Johnson & Johnson's agreed 1.75 billion euro ($2.4 billion)...
New York Times  Feb 9  Comment 
Shareholders of the Dutch biotechnology company Crucell approved changes to its bylaws and the makeup of its supervisory board, moves that will pave the way for Johnson & Johnson's $2.4 billion takeover.
Reuters  Feb 8  Comment 
With Dutch biotech Crucell about to be gobbled up by U.S. giant Johnson & Johnson , its chief executive Ronald Brus will need to deliver new vaccines quickly to make...
Reuters  Feb 8  Comment 
Crucell shareholders on Tuesday supported changes in the Dutch biotech's statutes and supervisory board, which will help Johnson & Johnson take control of the...
Reuters  Feb 7  Comment 
Dutch biotech Crucell swung to a full-year loss, hit by a vaccine impairment charge and higher operating costs, but said on Monday Korean regulators back the resumption of...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki